Podcasts about evestment

Have you ever been so distracted by your phone that you've missed important moments in your child's life?   Today's guest knows just what that feels like. Joey Odom joins me to talk about phone distraction and how it impacts our children's lives.    Joey missed his son's first soccer goal because he was looking at his phone, he had a realization: his phone was getting in the way of his best intentions as a Dad and husband. Since then, he has been on a journey to change his relationship with his phone so that he can change his most important relationships in life. He and friend, fellow Dad, and co-founder, Heath Wilson (co-founder of eVestment, a NASDAQ company), started Aro to help create a new generation of intentional families. Since launching in October 2022, Aro has been adopted by thousands of families across the country, helping parents model healthy habits for their kids, be more present with their families, and set their kids up for success with technology.   During our conversation we talked about: Setting boundaries and prioritizing face-to-face interactions. Tips for modeling positive behavior for children. Balancing screens and connections in modern parenting. Strategies for intentional parenting amidst digital distractions   So, grab your favorite beverage, settle in, and join us as we explore the intersection of technology and family life on this journey toward intentional parenting in the digital age.   And to learn more about Aro visit https://www.goaro.com/   Cheers, Christy  

Joey Odom is the co-founder of Aro, a disruptive technology company that uses technology to help us put down our phones and be fully present in the moment with the people who matter most. Aro's technology leverages the science of habit formation to create patterns and rhythms of presence for families. Aro is the only platform that quantifies time physically distant from phones, which studies show is the most effective way to limit personal device screen time. Joey is a natural storyteller and a dynamic leader known for his ability to inspire and foster deep connections with others. His own experience with technology as a husband and dad led Joey to help create Aro alongside co-founder Heath Wilson, former co-founder of eVestment (now a NASDAQ company). Joey also hosts The Aro Podcast, which is a weekly conversation with leaders and influencers who strive to live intentionally. Find Joey and Aro: Website Instagram --- Support this podcast: https://podcasters.spotify.com/pod/show/taylorkulik/support

Joey Odom is the co-founder of Aro, a disruptive technology company that uses technology to help us put down our phones and be fully present in the moment with the people who matter most. Aro's technology leverages the science of habit formation to create patterns and rhythms of presence for families. Aro is the only platform that quantifies time physically distant from phones, which studies show is the most effective way to limit personal device screen time. Joey is a natural storyteller and a dynamic leader known for his ability to inspire and foster deep connections with others. His own experience with technology as a husband and dad led Joey to help create Aro alongside co-founder Heath Wilson, former co-founder of eVestment (now a NASDAQ company). Joey also hosts The Aro Podcast, which is a weekly conversation with leaders and influencers who strive to live intentionally. --- Support this podcast: https://podcasters.spotify.com/pod/show/4fitfatherhood/support

Joey Odom is the co-founder of Aro, a disruptive technology company that uses technology to help us put down our phones and be fully present in the moment with the people who matter most. Aro's technology leverages the science of habit formation to create patterns and rhythms of presence for families. Aro is the only platform that quantifies time physically distant from phones, which studies show is the most effective way to limit personal device screen time. Joey is a natural storyteller and a dynamic leader known for his ability to inspire and foster deep connections with others. His own experience with technology as a husband and dad led Joey to help create Aro alongside co-founder Heath Wilson, former co-founder of eVestment (now a NASDAQ company). Joey also hosts The Aro Podcast, which is a weekly conversation with leaders and influencers who strive to live intentionally. 4 Fit Fatherhood Links --- Support this podcast: https://podcasters.spotify.com/pod/show/4fitfatherhood/support

BIO: As an accomplished entrepreneur and respected leader in the fintech industry, Larry Shumbres's mission is to continuously enhance the investing experience for both advisers and investors through innovative technology.STORY: Larry tried to create a hedge fund, 50% tied to digital gold and 50% tied to the top five cryptocurrencies but faced so many setbacks in the process. He spent too much time and money on this venture, which never paid off.LEARNING: Don't try to build an investment product around an unregulated industry. Don't invest in what you don't know. “If you don't know anything about private equity, derivatives, or options, don't do it. First, learn how it works and then look to invest in it.”Larry Shumbres Guest profileAs an accomplished entrepreneur and respected leader in the fintech industry, Larry Shumbres's mission is to continuously enhance the investing experience for both advisers and investors through innovative technology. He is recognized as an industry expert and has over 20 years of fintech experience with companies such as Charles Schwab, Morningstar, and New York Life Investments.Most recently, Larry founded, built, and exited Totum Risk, a leading risk tolerance platform for the financial industry, through its acquisition by TIFIN. Before Totum, Larry built SmartVision by eVestment, which was later acquired by Nasdaq. He also led the sales team at eMoney before its acquisition by Fidelity.Worst investment everIn 2017, Larry had the idea of building a hedge fund, 50% tied to digital gold and 50% to the top five cryptocurrencies based on market cap. He put a lot of time and money into it. Larry had another business partner that was also putting time and money into it. He even had some friends and family money tied into this venture.Larry completed the private placement memorandum (PPM) to enable him to sell the product and have investors review it. Larry faced a couple of problems during this whole process. One, he didn't have a track record. Two, he couldn't sell the product in the United States. Three, it was impossible to distribute the product in other countries that had their own rules and regulations.So after spending a lot of money on attorneys, consultants, rules and regulations, and licenses, it got to the point where it wasn't worth it. So Larry shut it down and lost the money.Lessons learnedDon't try to build an investment product or tool around an unregulated industry.Anything that the SEC hasn't approved is a big risk.Andrew's takeawaysRevenue is everything. As a startup, your number one goal is to get your revenue up as fast as possible.Actionable adviceWhether you're an entrepreneur or an investor, investing in what you know and what is regulated is wise.Larry's recommendationsTo review any investments, Larry recommends going to large financial institutions like Schwab, Fidelity, Vanguard, JPMorgan, Chase, etc. Such institutions have a plethora of information to help you learn about investments. But more importantly, if you don't have a passion for investments, Larry recommends partnering with a financial advisor to...

Heath Wilson is the co-founder of Aro Technology, Inc., a tech company that aims to help people put their phones down and live life uninterrupted. An entrepreneur, visionary, culture builder, and idea generator, Heath co-founded eVestment prior to Aro, and sold the company to NASDAQ in 2018. His experience in data-driven solutions coupled with his […] The post Heath Wilson With Aro appeared first on Business RadioX ®.

According to recent studies, the connection between employee well being and employee engagement are inseparable. Trends show that investment and development of human capital should be our top priority. Healthy employees are more mindful, happier and show higher rates of job satisfaction. Engaged employees show up to work with a bounce in their step, are less distracted and overall are less vulnerable to negative stress. Where engagement is low - morale is low. Where engagement is high - cultures thrive and organizations show 21% greater profitability. In this week's episode, Jenni has a conversation with Heath Wilson, Co-Founder of Aro, about how we as leaders and chief vision casters can be more intentional about modeling what it looks like to manage a very real distraction that hinders us from truly seeing our people and leaning into more meaningful interactions with those whom we lead. Heath is passionate about helping leaders, families, and organizations reclaim their time without technology and Aro is his way of doing that. Prior to Aro, Heath's 20+ year career was primarily spent at eVestment, a financial technology company he co-founded and ultimately sold to NASDAQ in 2017.As leaders, we have the ability to set the tone in our cultures by creating new habits and establishing rhythms to increase authentic engagement. Small habits are the building blocks to take you from where you are to where you want to go. In our everyday interactions, it is our responsibility to bend culture and create moments that hold the possibility of quantity for the sake of quality. For a next step, we encourage you to REGISTER for the Culture Conference 2022 hosted by The 4Sight Group. Culture Conference is a FREE digital conference, taking place Aug 11th that will provide practical talks from today's top leaders to help you continue to build thriving teams, cultivate inspiring workplaces, and achieve mission. Resources:Gallup ArticleLeadr (Mention “Jenni” for 25% off)Church Disruption SummitConnect with Heath:LinkedIn

Today we continue our series of interviews in partnership with Webb School of Knoxville. Each student in the Introduction to Entrepreneurship & Design Thinking course and the Honors Entrepreneurship class interviews a local entrepreneur. This episode features, guest speaker Heath Wilson, founder of eVestment and Aro.

In this episode, we sit down with Larry Shumbres, who recently joined Presults, the AI-powered compliance platform as CEO. Larry has an extensive background in fintech – helping launch and grow a number of tools at Totum Risk, Evestment, eMoney in more. Presults is doing some incredible work in the space and I wanted to pick Larry's brain on how advisors can continue to stay proactive with clients while maintaining clarity and cohsiveness internally and with their compliance partners.

Episode Summary:Elon Musk Sells $5 Billion of Tesla Shares$500 Shiba Inu Giveaway Guests:Ben Rabizadeh StoryTrading 10:00Vivi Biotech Queen https://twitter.com/Biotech_SD 24:00Zandy Forbes, Ph.D. President & CEO of MeiraGTx (NASDAQ: MGTX) 41:00Ronen Samuel, CEO of Kornit (KRNT) 55:00Scott Mathis, CEO and Chariman of Guacho Holdings $VINO 70:00Renato Capelj, Benzinga, Physik Invest 110:00https://physikinvest.com/Hosts:Spencer IsraelTwitter: https://twitter.com/sjisraelAaaron BryTwitter: https://twitter.com/aaronbry5Subscribe to all Benzinga Podcasts hereClick here for BENZINGA TRADING SCHOOL Get 20% off Benzinga PRO here Become a BENZINGA AFFILIATE and earn 30% on new subscriptionsDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Unedited Transcriptwe got a lot of guests today. Here's that's what I said. Here's what we got. We got Ben from story trading in like eight minutes. We've got Vivi biotech, uh, or the Bio-Queen at, uh, 1215. We've got Zandi Forbes from Mira GTX. She's a presidency yet.We're talking gene editing at 1230. We got Ronan Senor from Coronet digital we're talking, uh, fashion and the fashion supply chain at 1245. Did I get all that right? As far as timing goes. Yep. We got Scott Mathis from Gaucho holding sicker V I know, uh, at one and that Renato, uh, Capella, he is a Benzinger writer and also does some really, really cool options trading on the side.Uh, he'll be on the show at one 30. So we got what we got. 1, 2, 3, we got six guests today. We have all that's a lot, frankly. Uh, maybe a few too many, but nonetheless, here we are. So before we get to those guests, uh, we're going to talk about what's what's moving. We're going to talk about, uh, crypto. We're going to do a guest that sharp sediment.Cause we got some good feedback from that yesterday. So, um, AB where should we start? Um, well, let's start with just looking at the overall market. Spencer. I see Christian in the chat asking who do we have on for a guest today? You just ran through them, but you can also check the description in the YouTube, uh, the YouTube description for the guests for the day.Um, and shout out to the chat yesterday. We had some good trade ideas thrown out in the chat yesterday. We did, uh, easy Mike was talking about Uber puts. I played those. They were up nicely. Um, and we were talking about playing Disney for a big move on either side. We got talked out of it by our main man, Nick Shaheen.But yeah, I don't know. Maybe we should have done it. Yeah. I felt bad about that one going and they got talked out of it, but, uh, you know, it was a pretty brutal quarter. So, um, anyway, I don't even know why I look at Disney it's in my never sell portfolio. That's my first mistake is don't look at and stuff and your never sell portfolio.Otherwise you're just giving yourself anxiety. Rowan DAS pips is saying audio levels. Are we good, Bruce? Or Ron? Are you awake? I'm here. Okay. Oh, he's coming through us through the sky. I did not know that was coming from Terminator. I'm hanging out on the background, like a good idea. Hey, uh, while we figure out those levels, if you all want to do a solid, as DK suggested and hit that like button ladies and gentlemen, we'd appreciate that.Thank you very much. Um, Hey, what's do a guest, that chart segment. We're going to start doing this every day yesterday. Wasn't it easy one a B I don't even remember what it was. It was D whack. Oh yeah. That was that. That was yours. Full disclosure, I guess the one today. No, because I changed it. Shoot. So beforehand Spencer showed me the guests that chart and I guessed it and he didn't like the fact that I got it so easily.So he went out and picked a new one. I don't know what it is. I went out and I picked her from, Ooh, this will be a good drawer. And then he gets to like right away. So it's not a firms that don't get that, um, drop your answers on the chat and whoever's right. Uh, email us afterwards and we'll send you some swag.Um, here is two days chart of the day. This is going back to like February, or actually this is going back to the start of the year. This is going back to the interests of the start of the year. Now I will give you some hints because otherwise it'd be impossible. I feel like, um, in some respects, this is a technology stock in some respects.Oh man, we can have a winner already. Holy moly. Christian Gallagher. Wait, it was PayPal. This is PayPal. How so are we looking at weekly candles right now? Is this a daily PayPal has gotten beat up over the past month or so it looks like, yes, it has gotten beat up is, is, is, is a nice way of putting it, but yes, Christian Gallagher.Did anyone yesterday? No, Frendo on yesterday. Christian email us shows app benzinga.com. Hey, why is PayPal down so much? Didn't they just announce a Venmo, Amazon integration. So yeah, you would think that tell me you don't own PayPal or maybe you do and you don't know it. Um, I think in my like real portfolio, the one that I don't manage it's in there scourge.It's too easy with showing prices. Well, that's an idea. I take the price off ridiculously hard, but we could do that. Should I buy? I like calls on PayPal. No, it's gotta be coming back up at some point, right? That's one way of putting it. Um, you want to throw out like, uh, you know, you want to buy the, the, the, the, the two 80 strikes expiring and like six months.Really worth looking at. I'm sure it's not very much money. I do think though we have to, um, you know, keep up, like if we start doing obscure biotech stocks, you know, it'd be nearly impossible. So what we'll probably try to stick to, I dunno, S and P 500. Yeah. That's, that's, that's a good plan. Stick to the S and P 500.So we're going to do this everyday. Christian email us shows up and it's going to come. We will hook you up with some schwag before we go to our first guest AB I seem working backstage. Let's do our first crypto update of the day. Sure. Yeah. So yesterday Bitcoin spiked on the CPI data and then gave up all those gains and more.Let's take a look today to see how the, the crypto markets are responding to that yesterday. Uh, we, we have a lot of people in the chat that have been asking kind of how are they supposed to be trading crypto right now? So I know you and I, Spencer are in that boat where we're just like adding Ethereum and not really touching it or selling it.I haven't even added recently. It's been a while for me. I hadn't bought a theorem. I wanted the board. So yesterday, w like I've mentioned, once that CPI data came out, Bitcoin spiked and actually hit brand new, all time highs, um, gave all those gains up is currently trading about $65,000 a coin down 4.8%.Ethereum is also down, albeit not as much Ethereum currently, right around $4,800. So we talked about that $5,000 level being a big level for Ethereum. I think once we see a theory and finally breakthrough that $5,000 level, we can really see it run. Um, but yeah, everything pretty much in the red, like you can see from this heat map Sheba, he knew though in the green up 5%, um, we're actually going to have a big Shiba Inu guest on the show tomorrow.Uh, his name is Ross. He was an early investor and also a kind of co-developer of Sheba. So he's someone that I think I can say confidently knows more about Shiba Inu than 99.9% of people in the world. Um, so if you're interested in Sheba or what's next for the coin tune in tomorrow, he'll be on about one 30, uh, Spencer, any thoughts on this crypto heat map?I I'm trying to get a link right now because we're actually doing a sheep giveaway. I'm trying to get the link for that. I don't have it handy, but we're giving away some free shipping. I hope somebody gets me that link so I can get it to you. Uh, that's my thought, my thought is no. I mean, Bitcoin is an inflation hit crypto isn't inflation, hedge.Um, I don't quite understand the why it's down like this today, but you don't. All you need to do is look at the reaction to Bitcoin at 8:30 AM. Eastern time yesterday, right? Inflation comes out. It's harder than expected. It's it's more than expected. What does Bitcoin do? It goes up. Mike is saying, Hey, be it.It's a good play. Definitely go for PayPal options. Um, so I don't know if he's, you know, facetiously saying that he wants to see me lose some money, but I'm looking at him. I'm looking at the calls. Um, but yeah, Spencer, like you mentioned get some free Bitcoin we'll we'll throw that zing token up real quick.Go to Voyager. You put in a hundred dollars, you get $50 free Bitcoin, if you use the code zing. Uh, so not a bad deal at all. I mean, who doesn't want $50 of free Bitcoin checkout Voyager for that? Use the code zing. Um, all right. Real quick before we get to Ben. Yeah. Yeah. And, and I'm going to post the link to the ship giveaway.Um, when I, once you find that I find it. Yeah, no problem. Somewhere out there, easy Mick, you might be the guy who knows technicals what they're talking about when it comes to technicals, I'm watching a. Dash, which has been up a lot over the past, I don't know, week or so. Is this, is this, this the kind of subtle head and shoulders forming on the, on the one day chart?I think we're looking at five minute candles right here. I see one shoulder here. This could be the head, if this is the, the second shoulder, um, you know, could it start falling down or should I be looking at some dash puts, I need someone who knows technicals better than I do to let me know if this is, uh, you know, I'm not a big patterns guy, so I'm not really know, but we have some people out there that are outsourcing.And I know, I know when I need to listen to someone that knows more than I do. Yeah. Um, Alvin say, and he's looking at Wayfair puts an ADSL. K what's ADSL desk. Autodesk. Yeah, by the way, I just put the link in the chat for the ship giveaway. There it is. There it is. You can't click it on the screen, but it's in the chat.I'm just throwing up there. So y'all know it is there. All right. Y'all so story train. If you guys have watched a show before you've seen Ben on the show, he gave us a E H R at, I don't know, four bucks, three bucks. What does it now? It's like, I like 20 let's check real quick before he comes on. He'll give us an update on AHR.Um, it's at $23. So let's see. I mean, it's, it's up. I want to say like at least 200% since he pitched us to us on the show, he's got a couple more stocks. We're going to talk about, uh, Should we bring them on easy MC RSI? Isn't it. If the RSA is 90, isn't that a sign it could come to? I don't know. You, you know, more about technicals than I do.Let me know. All right. Without further ado, let's go ahead and get BenOh, Ben, what was the, what was the price of AHR when you first came on the calendar? What's up guys? Yeah. When I first came on, the show was around $5, five 40, somewhere that somewhere in the low fives, I believe it was. Yeah. And when we first presented it to our VIP community, when I presented as a trade idea, it was $2 and 74 cents.What, all the way up to 27. So it was a 10 bagger if you captured that. And I happened to pretty much captured that I was done. I'm handing this from 2 74. I didn't sell my first shares until 16. And then, um, I sold a lot more in the, in the 20 to 25, 26 weeks and maybe even gotten a little bit at 27. So, um, yeah, I've got a few updates for you on, on that.And a couple other sucks. Yeah. You got a new background. This is the first time we're seeing this. It looks pretty good. Yeah. A lot more work to do. We got to get that our mikes and cameras and everything, but yeah, this is the first time anyone's seen this background. Cool. And you said too, it looks like we did.It took us far too long, but we eventually got it together. You get a zoom out so Ben can see our beautiful. Oh, wow. That's great, man. Um, all right, Ben, you want to go ahead and get your screen shared and we can go ahead and run through those slides real quick. I know we only got about 10 minutes, so we've got a few I'll work.I'll be fast. All right, there we go. All right. So yeah, first we got that quick disclaimer, we got to always do that. A story is not investment advisor and missing his spirit is in most gimmick where some losses of you who are new to store trading, what is associate is the practice of understanding market pricing.We also call that the story behind the trade through the four pillars, which we say are sentiment catalyst, fundamentals, and technicals. That allows us to take a holistic look at markets and make choices based on all of these factors, not just one of them. So air story, trade idea, update. I officially opened that in my community on July 8th of 2 74, I did close it on November 8th of 25, 79.I still own some shares. Uh, I ended up selling about nine giving 95% of my shares. Um, Monday morning was really the trigger for me and that's because I saw something, the technicals and also the sentiment, which caused me to say, let me, let me lock in these games. And the technicals last Friday was the.Solid green candle on the chart, you can go look it up the first solid green channel and then tire run-up, which, which means it started the day high and then went down lower throughout the day. And throughout this entire run, it was starting low and going higher throughout the day. I took that to be a reversal sign plus the sentiment, I think when reached peak Eby sentiment for now, for this cycle with, uh, Elon Musk selling shares of Tesla with the Caribbean IPO, with excitement, but Eby infrastructure.I'm trying to time that sentiment top. So I took my profits. I am keeping about 5% of my shares because it could go much higher still if they get the right contracts in the future. Got it. Um, so it took some money off the table, trim some of your position and air took those profits, never a bad move. Uh, Ben, what else?I was on your radar today. I wanted to give you an update on side, cause I was on your show. July 26, we presented this at $5 and 70 cents. Uh, this is stuff that's been up 66% since it was initiated in our community. At the time we said, Hey, T-Mobile's come in. End of month in August. It didn't happen then.But it happened last night. Uh, so a few updates. They have earnings last year. Um, so this T-Mobile deal came three months late, but it's finally here. Now, key, this was announced last night on the conference call only. There's no PR yet. So people who are in the know who are listening to the conference call, they have a big edge getting into the stock right now.Um, there probably will be a PR at some point in the future, and there's also tremendous traction with their other customers, 18 T and Verizon. Um, there was an upgrade today to $9 and I'm not even sure that Benzinga caught it, that upgrade by the analyst and $9 by lake street. But we think in our community, it can go much higher.Uh, there's uh, estimates out there in our community saying we can do go up to a dollar 33 DPS by 2024, which would be a $40 price target. So that's the update on SSI. You know, our investigative research worked and we're read about T-Mobile just a few months late. So this company is going to start printing lots of tests going to be a very profitable company.Do, do you have a target? Um, yeah, no, I don't have to stop losses. God forbid men. No, I do stories yet. I never do stop losses. So I've been holding the stock for like two or three years. I increase in decrease my position around catalysts. So, um, I was buying and after hours last night I bought a lot more today.It's now my largest position actually. And uh, I'm not going to put a price target. I see how it goes. I, I assess the fundamental sets of metallics and technicals on an ongoing basis to determine. There you have it. Yep. So I do have a new pig that I'll get to in a second. But before that, just a little quick alert, maybe something for you guys to look into and talk about, because this is a big kind of big cap for us.At $1.5 billion company GoPro. We presented it to our community Sunday night, um, because the fundamentals are super strong. They had earnings last Friday and we have anticipated a technical breakout of the 200 DMA, which just happened this morning. And this is really, it could be a really fun situation, wanted to bring your attention because it has, this has short and gamble, squeeze potential, very high, short position.He has sense of it has been very, very low, but the financials have completely turned around with this company and they're printing tons of cash. Now you see the technicals broke. The options are very liquid, very cheap. And if it gets into the right hands and the Reddit community, et cetera, this could be a crazy profit potential, you know, with shorten game of squeezes.So keep your eye on that. But go. So GoPro's up about 9% today on the strong earnings. Um, so I, I mean, I, I don't know, personally, Ben, if I'm going to go in and try to chase GoPro and it's already up 10%, but I, or 9% today, but I definitely like having it on my radar. Uh, J rice in the chat was also talking about GoPro saying that he thinks it could be a long-term turnaround play.Uh, I don't know. Munis has been one of those stocks that has just been like beaten down over time historically. Um, but you know, at some point I don't think you can ignore the fundamentals or Fridays when I got in added more Monday, uh, I got a little bit messed up on the options than playing the options.So I actually lost some money. Cause I got scared with the whole inflation thing yesterday, but I'm in it now and yeah, the sense of it's sport, that's the only thing people hate this company, but they're printing cash like crazy. The technicals are turning and shorting, given squeeze potential, such that this, yeah, my all hold back a GoPro has always been that.I feel like they have a very limited, uh, customer base, you know, it's like who, who who's going out and buying GoPros. It's people that take part in extreme sports, you know, mountain bikers, snowboarders, skiers, et cetera, outside of that. Um, I don't, I don't know how many, you know, everyday people are GoPro customers.It's absolutely correct. And I'm not, you know, I wouldn't take issue with that, but the amount of earnings they have like 60 million EBITDA this last quarter. And if you compare it with their market cap, I mean, this thing can easily be 17 bucks. Even with that knock against it. Got it. Um, I been, what else is on the radar?I have a presence. It's my first story. Trade ideas. Since air. I presented this to my VIP community last week. Okay. Listen to the presentation. Don't just jump into buying guys. Okay. Because of what happened with their, every stocks, not air, I can guarantee you, this is not going to go a thousand percent in the next three months, like heritage.Okay. So that sock is Gaia, ticker symbol, G a I a. All right. So we're going to look at it and yeah, it's a smaller company on the ground, 200 million market cap or so, but you know, what's the story behind the trade. That's what we're trying to figure out. And again, we look at the sentiment, the fundamentals, catalyst and technical.So let's start with the fundamentals guys, digital video subscription service, like in some ways like, like Netflix, they sell, um, they make original content for yoga, alternative health, holistic healing, nutrition. It's a monthly subscription service. They've been growing steadily over the last many quarters.They're profitable. Uh, fundamentally I think their inflection really happened to a quarter or two ago when they became profitable. And you can see some of the, uh, the trends here in terms of their, um, their revenue and their EPS, although in the right direction. So in our community, we collaborate with people who are really steeped in fundamentals, just charts, courtesy of Mark Holmes.He has a risk reward chart here in terms of what is the value of this stock and. You know, it's worth, it could be worth at least $17 a share. And the stock is very cheap here. So, so that's the fundamentals. You can check it out on your own. Go look at the earnings report and you'll be able to verify everything I'm saying about, uh, the growth and the subscriber growth and money they're making written it now.And it could potentially be, uh, you know, Netflix may buy them out one day. You know, there's, there's a lot of opportunities here. So, um, yeah, catalyst let's go to the next pillar. Uh, in these sorts trading four pillars, they had their earnings just recently, November 1st, it was 20, 20, 20 2% revenue growth, uh, year to date compared to last year Q3 EBITDA of $4 million.Uh, even a margin of 20% was their fifth straight quarter positive earnings in cashflow. Um, and then they had an additional catalyst the next day. So we'll talk about that catalyst in just a second. What happened the day after earnings, but first let's go to sentiment. So the sentiment is kind of poor with the stock because fundamental investors are frustrated at the price action.I know a lot of fundamental investors saying this should be worth 17, 20, 25 bucks. Why is it $10? Why is it moving yet? So I listened to other participants. I say, I talked to people in social media. I talked to people in my community. Why aren't you interested in the stock? And this is what I'm hearing.The total adjustable market may be too small. It may be too niche, their content. We talked about alternative medicine, yoga, meditation, and things like that. So it feels like I'm just not interested. It doesn't seem like a huge part. Other people say, Hey, the content, they have some content that's kind of fringe on their French content.Like some of that alternative medicine, there might be some videos on, you know, some vaccine hesitancy type stuff or who knows, like some things are it's alternative content, right? So some ESG, uh, buyers, uh, may stay away from that environmental social governance. So that's another knock on the sentiment.The other knock is this is just slow and steady growth it's and where's the hockey stick potential on that. So just remember, this is the poor sentiment. This is what happened. Going back to the catalyst the next day after earnings, after we know the fundamentals are great, the next day another catalyst hit the other, the catalyst was there was a PR that Demi Lovato became a brand ambassador for.And there was a press release that a lot of people didn't see a where Demi Lovato says I'm excited to be one of Dias. First celebrity ambassadors, and honor to join a platform. I've been a fan of for some time she has 118 million followers on Instagram. And the market cap is again like 189 million. So this company has been growing slow and steady.And all of a sudden, they hit you with this news of Demi Lovato is a huge mainstream personality, that and company, I want to go back to this. Airpoints the one thing I saw that the thing about Demi Lovato, uh, in, and I, I guess I didn't realize this was the same company, but like they got a lot of weird shit on their platform.And that was the sentiment I was talking to. They're saying, oh, there's stuff is weird. I just don't want to own this company. But you know, I think that, you know, they're growing steadily, they're getting to a place where they can really focus on growth now, and to me, and let me go back to that bad point.You just made that pinpoint. You brought it up for me, right? Yeah. They have weird stuff. It's too niche. The French content. They keep some buyers away. But this is where I think that Demi Lovato news is really significant because they're in a financial position now to really grow the company. And to me, this signals.And in fact, in that PR said, I'm excited to be one of guys. First celebrity ambassador, And I have a feeling this company is going to start growing their content and start getting into more mainstream content. And based on what you're saying, I think they may be looking for more celebrity ambassadors.And it's just a great situation because the downside is so limited. You have a fundamental floor here and now you have optionality upside. If the company starts doing things to get that hockey stick growth potential. And that's why I really add it to my position here. And I'm very excited for the next several months on this stuff.Um, let me just go to the last or technical resulted with her awesome technician Rex. And this is a monthly chart is saying, uh, this can go to the twelves if it breaks out of the yellow.here, which thought is that shorter than I think the current breakout circled right there. It's got a breakout of, I guess, 10 70 area.He thinks it can go to 12 for the month. And here's another view which looks much more bullish. This is a long view of the monthly chart is a sometime in the future. When the 12 to 13 breakout at the blue line, it should proceed to break out the all-time trend at the white line. And he thinks this is a several month play for that to happen, but you can kind of see where this can go.Uh, if that happens. Uh, any questions on that or any of the other stops, man? I didn't see this one coming. I didn't realize this. I read about this company and I was like, man, I didn't even realize they were a public company until you came on here. So, um, I'm all I'm putting two and two together here. Uh, Ben, thank you as always for coming on the show, we appreciate it and uh, and have a good rest of your day.Please follow us on YouTube. Thank you guys. Thanks a lot, Dan. We got to get moving. We got our next guest. She's already here. We're going to talk biotech guys. I know that we, we always get asked. We always get questions like when's Vivian. When's Vivian. When well she's on right now. Not right now. She'll be on in like five seconds when we bring her on.But Vivi Bio-Queen will be joining us every Thursday. At this time, I told you all to save your questions for your bites. The questions for right now, let's bring her on Vivi. How are we doing today? Good. How are you guys? Can you hear me? Well, we hear you. We see you and we have questions. Oh, awesome. And before we do any questions, I think, um, we can do some updates.I did have a request on Twitter to cover it stock. Um, like at my old good lawyer friend, mellow at Twitter, I, this is out for entertainment purposes. So, uh, is only my opinions are for entertainment, purpose, not a financial advice. So I wanted to, uh, first of all, um, talk to you guys, um, just given up a date, we just had the, uh, ER, on KMP.H can you guys put that up over there? Yeah, this is a daily chart. Okay. And P Hit's quiet. So, yeah, so we just had the ER and I want to, so when I, when everybody kept asking me, like, what do you, what are you going to do for 'em? What are you going to do for K MPH? My position was this small because he is a, some of the concerns I had. I spoke to the manager and he interviewed me. And, uh, he said, you know, we're not going to put any reps in New York yet.And it's just going to be certain regions in the United States. And for me, it showed a little bit of a weakness because for me, if you launching a drug, you should have put reps all over the map. But I think they're just trying to be cautious. So they report around like, I think 2 million in revenue, but here's what I'm bullish.Now. They just launched the rest of the Salesforce. And this company here, you know, their burn rate is really, really small because Korean is doing all the selling. So the burn rates is like a million a quarter and they have a, still have 135 million. And he is what I'm bullish of. Um, there's a company that sells a scripts and there's a guy that, uh, his friend works for this company and feeds him all the script.So for you guys to have an idea, right, the, the feedback has been amazing. So July, they had a nine scripts for the monthly and then August, they had 173 scripts, um, September 416, October 886, still low because there were not out throughout the nation. But I think the feedback has been tremendous from psychiatrist, from the drug and the differentiator.And I feel like as they deploy, uh, the other sales reps, we going to just ramp up the sales. So I feel like at this moment, I wanted to add a little bit more to my position because I, I see the future being very bright here, KMBH. And I think that, um, we gotnot yet. Not yet. I, I should have now I have an, I am waiting for some of my swings to flourish, so I haven't been able to, to add, but I wanted to for sure. Okay. And then I want it to put you guys out. Somebody asking me to, uh, to, uh, cover a, uh, a N N S. Hmm. Okay. Now I want I'm familiar with, but it is biotech.So it's a biotech it's under the radar. So I wanted to explain to you guys some of the reasons how I invest in biotech, and I told you guys, if there's no commercial products, there's, there's got the most important thing you can look at is cash, right? Because if you don't have a cash, no product, are they going to burn too much?And they also gonna have a, to do offerings. And if the stock is low, they do reverse the split. So the first thing I do is to look what was the cash burn and how much cash they have left in a would the future and what the catalysts are going to be. So this company here, the first thing that got me to, to look at it was they have a $271 million in cash.So they're really the city really strong. So I thought that was a really, really, uh, um, uh, valid, uh, information, very important. Then I look at a financial institution on. EVestment, which is a goblin, was the director of FDA is a partner on their firm. So they own 2.5 million shares. So I thought that was another very important information because goblet is well connected to FDA.Not that you know, it nobody's going to be bought out, but when you have investors that work with FDA, they know what it takes to, to be compliant, to get a drug approved, right. Because it's just so much behind to get a drug approved. So manufacturing, you know, how the studies are designed. So I like the fact that there's Nia investment behind.And then I also know VOD is, oh, 2.1 million. So Novartis has some interested and, and the pipeline, it looks really, really amazing is all CNS, um, uh, and mass. Um, they're going to have, uh, Gilliam Barre syndrome, which is a very rare disease. So I really like this company. I really do. I, I'm not, uh, obviously I can't be in every single stock.Uh, but I, I, I, I think this is a really good a long-term, uh, stock to hold for sure. So that would be one. And then if you can, um, bring back, uh, pro GPRO G we have a lot of fans PRG. It's like almost like a min stock, but also a really good stock to hold long and, um, really. Yes. Yes. So, so what, what do you see that the market doesn't see, um, what I see that the market doesn't see.Um, I will tell you why this company is going to be huge. They have a two types of, of delivery system. They have a, um, on, I'll tell you guys, they have a two to two technologies and I wanted to bring to you guys, let me see. I can share a screen. Okay. But I have it here right in front of me. So they have two things.They have the OBDs okay. Which is oral Biotherapeutics delivery system. So what it does is, is able to take big formulations and put in a form of a pill. So for example, Humira is one of the biggest blockbuster drugs in the world. If they found a $10 billion. So you imagine if Abby, I think Abby is a Humira honor.If, imagine if Humira is loses patterns and five years, right. And all of a sudden, because doctors love the efficacy of this drug, and that's why it's so well prescribed. Right? But it's an injection. Imagine for this company sell their technology. And all of a sudden you can have a drug, like a Humira being, um, given orally, all of a sudden you create a whole new patent for that drug.Do you follow me? Because a different formulation. So all of a sudden you gaining another 15, 20 years. I have a patent on that drug. Now imagine how many pharmaceutical companies would have be jumping all over because they like, geez, I have this, this drug that's high formulation. And now I have a, I would love this drug to be an oral form because patients do prefer to be an oral form.So I see, um, they announced that they have three partnerships with the big pharma, but they have announced who, so everyone is kind of on a suspense, like who are going to be the big pharma. So they have, uh, right now with the Pfizer there, just to have an idea, they, the not only the delivery, the delivery system does this to the big formulation, but also one of the drugs of four in any boat to the second one, the oral bio biotherapeutic delivery system.The OBDs, what it does is it's designed it to, to, um, to take it a pill and the pill, the way this delivers it, doesn't go all over your bloodstream. So it's it's for the GI tract. So is GI specific drugs and there's one. For for, for, uh, uh, Pfizer they're there. The preclinical, what they found was not only that, that would their delivery system, that drug was 25 times more potent than the Pfizer drug, but had a no toxicity because it doesn't go to the bloodstream.Like the other drugs would go. So you have a less toxicity, less, less side effects. So imagine what they can do if they already doing this with Pfizer drug, they're studying the Humira. Imagine like for me, this drug should have just literally like get royalties for every farmer, choose the technology instead of it being bought out.Right? So I believe this, the future of this company is super, super bright. Uh, you know, it's heavily shorted. So I think that a lot of people are here for the, the, the, the gum is squeezed because if you look at the amount of, of, uh, of, uh, options, that the options chain is crazy, uh, for this, for this company.But I, I will, like, I have a big position because I wanted to, you know, to trade around my core, but it's some, it's a company that I wanted to keep it. And, um, and a long term, uh, option, because I feel this company is going to be huge. So they just appointed also geo hall, believe it or not do, how do you, how, um, she's in a board of directors and this woman, it's like a powerhouse in biotech, a friend of my work.As so maximum, so messenger gas sold. So she comes in with a lot of experience in pharma and a lot experience in acquisition. So, uh, the team is fabulous. They are four miles away from my house. I should have just bring them a bottle of champagne when we hit $10. But I believe in this company, this company has a bright future and that, um, right now there's a lot of people on it, you know, waiting for that short squeeze.But, uh, it's been keeping really it's being holding like it dipped to, to like 2, 3 0 3 today and it went right back up. So it's been keeping, you know, I think the short sellers were expecting after der cause you know, there's, you know, a yard for a state, uh, initial stages of biotech doesn't produce revenues.Right? So it, it dipped to fund 360 2 all the way to three, but it's been holding for weeks at that average. So people are not selling people believe in this company for sure. Uh, can I ask you, what do you, what do you get, do you have any favorites in the, in the gene therapy space? I do. I, um, I, uh, I, I'm a loan holder for ADP and they have the, uh, it's one of the car T therapies, but it's not the car T is the RTC, uh, ADP.And, uh, the reason I like this company is, uh, not only they have a partnership with Genentech, uh, the Genentech partnership is up to three. And, uh, they already have enough funny from Genentech cause they got, they gave them a prompt payment payment. They have funded into 2024. So I feel like this is a very safe play in regards to not having offerings and that they are sitting with 285 million in the bank and they do have, uh, some, um, some, uh, catalyst coming.And, uh, I, I believe this company will be a multibagger on day, you know? Uh, so it's one of those that you set and forget it, but I like the position of cash because it gives me the comfort that they're not going to be throwing in offerings after a big catalyst. You know, they, they have they're in a really strong position.And when you look at, uh, um, institutional ownership matrix, all 15 million shares of this company, baker brothers owned 18 million, the institutional ownership. It's so strong in this company. And obviously Jen at that has a huge, huge portion of the company and has their eyes on the company. So, uh, this, this is a big one for me.I got to ask you about, about BCR X here. That's the rule. Every week we got to talk about BCR ex of course, it's this year access to my unicorn. You guys, for sure. So, um, it's, it's funny. I held this space as on Twitter yesterday, and I was talking to a pharm D you know, I do respect, they have a lot more knowledge than me, you know, uh, in terms of a clinical.And he validates my position on the CRX and GRTs, which is great stone. And he says to me, you know, be CRX is, is a rare diseases monster in the making. So they, um, they just released the earnings. They put 38 million for the quarter, and people, BU people were really upset that it wasn't 7 million like this huge numbers, but for the mentally long-term, it's still there, right.Because the science hasn't changed. So I see this as an amazing opportunity, uh, if you're not in the CRX, but, uh, just, you guys have an idea. Uh, the biggest drug for, um, for Alex yawn is, uh, Alto Morris. And they are not even that good because it's not only an infusions for PNH, but patients still need transfusion, uh, taking this infusion every eight weeks.Uh, BCRA X has the competitor, which is going to be an oral oral, uh, competitor factor D and not only patients that have been on this study up to now, not only they jumped from phase one to phase three, because they did so. Patients to this date. I think there's 40 weeks, 30 weeks of, could it be this fusion to this date?So imagine having a drug that is, it's already a rare disease for PNH and patients only at the choice on the available is in Jackie, no infusions. And you still have to go through the transfusions. Imagine having an oral pill that you don't have to have a transfusion at all. So just make them do the math and Alex, the on 70% of its revenue, 70 was on PNH for this drug and they got bought out for $39 billion that would have put the CRX at a $230 a share.And B CRX has a better pipeline with a more potential and it's going to be all oral. So you guys do the math, if you don't think this is a monster in the making. Alright, Vivi the bio queen, she joins his every single Thursday at biotech. Underscore SD is for Twitter handle it's up on the screen. And uh, and then please.Yeah, please, if you, I will post my DD there because this is a very short, so you guys searched the bioclean on Twitter and you can find me all right. Thanks a lot. Viva, talk to you again next week, next week. All right. Uh, Hey, let's stick with biotech for a second here because our next guest is the CEO of a gene editor.Company, hence why I asked to VV about that one to get her thoughts. So, uh, if we can, let's go ahead and, uh, and, and, uh, bring her on guys. Andy Ford. She's the president CEO of Mira GTX. His company is a lot going on right now. They're at a very critical point. So let's get Zandy onum, Ford,by the way. Yes. Thank you. Thank you. Where we're actually, it's on our to-do list to get new music, but, um, thank you for, for, for the compliment. Uh, so as I said, it's a pretty critical time for, for mirror DGX. Uh, you guys just presented at, uh, uh, the virtual, uh, oh gosh, uh, the European society of gene and cell therapy Congress, right?Uh, yes, we did add three abstracts. Yes. Right. And then there's a, we're due for another, a little bit surprised when I found out you're on the calendar. Cause I thought you guys, you have another, uh, presentation coming up in a few weeks. I, I, I think I believe right. We do. So we have, um, quite a number of presentations in the second half of this year, uh, which included, uh, some presentations at the meeting.You just mentioned on our programs and our switch that allows you to switch gene therapies on and off with a pale. Um, related to what video was just talking about, actually, that's what I do want to talk about. I'm sorry about, and then, uh, at the beginning of December, we, uh, having a clinical update on our xerostomia program for patients who've been cured of had a neck cancer, but don't make saliva.So we'll be completing that study this year and we'll be updating on the clinical progress so far at the beginning of December. And then a couple of weeks later in mid December, we're having a science day to discuss in some more detail, uh, Ribas switch technology and our promoter platforms, which allow us to really optimize gene therapy.And for the first time switched gene therapies on and off with an oral drug and not just switched them on and off, but quite precisely dose the amount of gene therapy at a particular time with a dose of an oral pill. So let's talk about the switching via via pill. Yes, exactly how that. So obviously gene therapies are a virus which contain a gene and there's a coding sequence of the gene, which will make your protein, whether it's Epogen for example, or whatever, uh, gene therapy, it might be RPG or for the eye.And that gene is activated by a promoter, a regulatory sequence at the beginning of the gene. So that's the normal gene therapy promoter and a gene, the promoter switches the gene on, and it remains on for the rest of that patient's life, all that sells life. So you have persistently expressed gene therapy, but what we've been able to do for the first time is we do everything.I've just told you with the promoter that regulates the gene therapy and switches it on. But on top of that, we put into the gene sequence, a small sequence of DNA, which instructs the entire RNA produced from that gene to degrade. However, if we give a small molecule, but via pill, and we've got many small molecules, because we've developed this as a platform, it stops that degradation.It cuts the entire degrading sequence out of the gene. Produced RNA and you'd get the gene switched on as if it was never there. So for the first time we can deliver gene therapies, which are not on, so they're not producing weird proteins or bits of proteins. And we give a pill and bomb that I'll call it.The degrading signal is cut out of the RNA and you get a perfectly normal protein product.I guess I have so many questions. I don't even know where to, I like that all sounds incredibly complicated. Um, I guess, uh, how can you make sure that it works? So it's, we've when we set up the company, this was one of the technologies that we, um, we wanted to build and these switches made of RNA shape.There are thousands of them and bacteria. And for, for decades, people have tried to take bacterial switches and make them work in human cells. And rather than doing that, which hasn't worked very well. We built, we use the theory of Reiber switches and we built based by base our own switch. So we built it in mammalian cells.We then tested many switches and we have a platform of switches we can control. We were able to make these really simple switches, which switched on and off to high dynamic range. So 5,000 fold above the off level when they're switched on. And as a consequence of that, we were then able to change the drug that we activated with.So now we have multiple genes that we've put our switches in sitting in our freezers. So, uh, various antibody, PCSK nine antibody. You'll be aware of, uh, PD, one antibody, the, the very large drugs we can regulate. And then other drugs like GLP one, obviously a diabetes and obesity drug, which we can regulate.So we've got those genes and we can now put them into vivo in mice and NH PS, and we give those animals small molecules and we've already shown. Based specifically on the dose of the small molecule, we see our drug switched on to exactly the right level in each animal, depending on the dose of the small molecule you give.So we have built this over the last five years and we have moved from cells to mice, to non-human primates. And we're currently in a position to start doing I N I N D enabling studies for both the small molecule, all drugs and the genes that they regulate. Uh, and then as far as use cases, I know you're working on, um, you know, you're working on applying this, um, to, uh, I disorders, right.Uh, but is that the only use case right now? Tell us about the other one. No. So, um, we developed this technology of controlling gene therapy with a pill in order to much more broadly open up the space that gene therapy could be used in. So. We do have a lot of expertise in the eye and a partnership with Johnson and Johnson for our rare eye disease programs, but in diseases like wet AMD or dry AMD or uveitis, those large diseases.These are targets for regulation with our cassette and small molecules. In the case of our wet AMD program, we inhibit VEGF like other companies do. But what we're able to do potentially is when we put that gene that blockades by Jeff into the eye, we can formulate one of our small molecules. That's otherwise oral into eyedrops.So what we're working on now is turning our small molecules into eyedrops. So we can put a wet AMD drug or uveitis drug into the eye as a gene and switch it on each day with an eyedrop. So the eye is an excellent place to be able to regulate gene therapy with a small molecule, another place, which is really important is in the brain because it's very difficult to get antibodies or biologics across the blood-brain barrier.But what we're able to do potentially is we have regulated antibodies and we can put the. By an injection into the brain, just a one-time injection within the blood brain barrier. And then all you need is a pill which crosses the blood brain barrier. So it allows us to deliver drugs that really hard to deliver by other routes.And there are many, many more applications. It, it hugely expands what you can use gene therapy for, because for the first time you can control how much you gave. And at what time, uh, it seems like broadly speaking Zandy, um, gene therapy, like what, like as an investment, it was like super sexy a couple of years ago.Right. And then it sort of, it was super hot and then came down a little bit and was like, oh, wait a minute. This is still really days. Where, where are we now? Are we like back to, is gene therapy being like the hot, the hottest topic in biotech? Or, or are we still sort of, is it like the off cycle? I dunno how else to phrase it?W well, I think there are, there are many different gene therapy companies and there is cell therapy companies. There are very, very large number of, of, uh, therapies in the genetic medicine space. And, um, and there are some companies that just have a product or a platform or a particular organ that they focus on and that.Is a somewhat higher risk to those companies that depend on data around a particular study, right? What is quite different about mirror is that we established the company to really innovate in gene therapy and shows indications in the clinic that had good proof of concept and highly likely to work and to support a future pipeline.We built everything you need to be a gene therapy company in-house so we have multiple promoter platforms, multiple capsid discovery efforts. We have our own internal manufacturing, which is probably the broadest engine therapy today in that we manufacture our own GMP plasmid. We have two, uh, viral vector manufacturing facilities, which are flexible and scalable to commercial scale.And we do our own QC and analytics as well as potency assays. So we have a very, very broad, I suppose, toolkit that's required for anything. That you need to do in gene therapy and went out, positioned with this regulation ability with a deep pipeline of regulated genes that we can then take through to the clinic with our vector ecology and our own GMP manufacturing,not of the regulatory by putting all that in house. I was just gonna ask, as, as we get more developed in this space, like Spencer said, it seems like a couple of years ago, you know, that the gene editing space was huge for investors. Uh, what advice would you give investors that are looking at different, uh, you know, genomics companies to, to be able to discern which ones are going to have an advantage in the, in the field once the industry does become more hot among investors?Again, I do think that right now, manufacturing is not just a bottleneck with respect to capacity, but, um, Dealing with regulatory agencies globally and an expertise in manufacturing process. And, uh, and the assets required to show the release and stability of your products is very, very important. And to be able to either have that, to have as much of that as possible in house dearest clinical programs that you'll see, particularly if you have those sorts of capabilities at the time of D you really don't want to see companies that are starting manufacturing their product in one way.And then at phase two, switched to another way and then have to scale it later. Ideally, you would look for companies that have capabilities that allow them not to necessarily rely on CRS for plasmid manufacturing or in DQC. And we learned that over the last five years, it's one of the reasons we've bought, uh, so many of these capabilities in house, but I do think that's very important.Um, in addition to obviously, you know, do the targets work or is this, is this an appropriate, um, disease for gene therapy, the nuts and bolts of being able to produce and show the agencies that you've produced the right thing, a really important. Zanni Forbes is the presidency of Mira GTX. As I mentioned, there's a lot going on.You guys also got some positive in Canberrans over the weekend and, uh, uh, a lot of presentations after being in stealth mode for quite some time. So, uh, looking forward to seeing how things develop here and, uh, and, and, and good luck going forward. Thanks a lot for coming on today. Thank you so much. All right.Hey, w we got to keep the train running on time here. We've got so many guests today, back to back to back to back let's pivot. If we can, maybe we just spent the last half hour or so talking biotech, uh, let's pivot to like supply chain, specifically, uh, supply chain of textiles, right fashion. And what exactly is going on there?What to find out? We're going to bring on our next guest here in just a second and running Samuel. He is the CEO of a cornea technology, and, uh, let's bring coordinates and a Ronan. W that's been running on this show. Now, if we can guys, I guess I'm Spencer, I guess I'm doing that. All right. I got you right.There you go. Good morning for us this afternoon for you it's later on in the evening. So I appreciate you, uh, coming on, uh, the, the, uh, the show here today. So, uh, let's talk about textile supply chains, right? Uh, what exactly is going on there right now are things as bad there as they are in other areas of the.Well, um, yeah, it's bad. And it has to change the supply chain is broken, but even more than that textile industry and fashion industry in particular is the second most polluted industry in the world. Um, from different reasons. One of the reason is that 30% of whatever put use on textile is actually never been sought.Uh, and this create a huge amount of waste, both of materials and water, and we have to save the world. Um, uh, so we have to change the industry. Now, the reason for that is some of it is because the supply chain of today doesn't meet or doesn't fit the need of the consumer of today. The supply chain of the textile industry is like centuries ago, you produce in large quantities in forest, in China, in Magilla dish, you trying to forecast what the consumer, what the people would like to buy a year in advance, sometimes 18 months in advance, which is impossible.It's crazy to think that you can predict what the consumer today would like to wear in a year and a half from now. So we have to change it. The world move to digital in many, many industries. And in this industry is still fully. Yeah, I'm glad you brought up the, uh, you know, the environmental impact of the textile industry, because that's something that's gained a lot of attention over the past year or so.I mean, you have a quote unquote fast fashion companies, such as sheen and people have kind of started attacking the, the idea that, oh, buying, you know, a cheap t-shirt for $15 or some pants for $15 that you see an ad for an Instagram, uh, causes a lot of environmental distress. So what do you think needs to be done in the industry to address that?So they, this would need to change in order to try to predict what the consumer would like to buy and put, use Lauder moms of products, which will never been sold is to produce, to demand, to produce after the consumer.But that's not efficient. I mean, it you're saying it is, but that's not a necessarily inefficient use of capital though, right? No, no. It's, it's actually a very, very efficient, um, hold on, explain to me, explain to me, yeah, let's begin with, first of all, what we see that production is really moving on shore.Why it's moving on shore, not only because the, the, the supply chain is broken because you have to be closer to the consumer. You have to react fast for the consumer trends. Now, the world of fashion and textile move is moving online today. 30% of all purchases being done online. So e-commerce the focus by 2025, that it will be more than 60%.Now, the online the e-commerce of today is still trying to sell you what they have in the inventory or what they have in the shops, in the stores. Uh, and if you going to order products, sometimes it does not exist at all. Um, and uh, sometimes, um, for the brands is really, really difficult to. Okay. Can you hear me okay?Yeah, we, we, you we're fine. We just got disconnected, but we're back. Okay. So, so I missed everything you just said. Okay. Okay. So let me try to explain again. So the world is moving digital. What does it mean? The consumer today's buying? So e-commerce online. 30% of all sales is being done online and the focus by 2025, that it will be 60%, but the online is today's actually a mirror of the store.Doesn't allow you to choose your product. They're trying to sell you what they have in inventory, which doesn't fit what this consumer would like, what we believe needs to be done, that the online should be filterable. You shouldn't have any real physical products. You can have endless amount of product virtually and connect the virtual wall to the physical world.And this is exactly what committee's doing is enabling on demand, production. You order what you want only. Then you produce it. You produce it close to the consumer. Onshore and delivering, you know, the same day on the next day to the consumer, the product, I feel like this is I'm in now. It sounds great. I think that, but that's like, that's more difficult, right?Well, I give it a few examples. Well, one example, great example. Thinking about the books book markets, um, back at 25 years ago was fully analog. You went to a bookshop, you tried to buy a book. You only have them, the shelf, the books that we're selling in millions of copies, Amazon disrupt this market. They created a digital world.You could go to Amazon buy any type of book, even from 200 years ago. But what they create is actually much more, the impact was much more than that because now everybody can become a writer. You can write a book about your family, about cooking, about anything you like, you publish it. Virtually doesn't cost you anything.Only when someone is ordering, then you print it and send it to the consumer. So the same thing is happening now in the fashion world, you don't need to have it physically. You actually unleashing creativity because you can have endless creativity and each one of the consumer can choose whatever they want in any Colleen, any design.And once you choose it only, then you produce. So this is efficient and there is no way. And you produce it using coordinate technology, which is a fully sustainable green technology. That was my next question was just if you to clarify that, so I come up here like Amazon, for example, uh, could have used your technology, right.Or, or any retailer, right? Could just buy your technology and, and use that along their supply chain to make it more and more green, more efficient. Right? Actually, Amazon is our biggest customers. Okay. Amazon is our biggest customer, but we have many, many more customer. We are worth more than 1000, 300 customers that using our technology all over the world.Some of them very big companies like Amazon, like Adidas, like fanatics, but using our technology. And you can go online and order products and customize the product and order your t-shirt here. You can see with coordinate on top of that or on any color, any size, any shape. And this is the new world. Look what the world is moving into.What is moving into metaverse. So metaverse is everything is virtual. You will have. Your image in the metaverse. Yeah. You will be able to dress it as you wish with any, any type of, of, of goods. Uh, and only when you feel that you lack it, then you order it and then it would connect it to the physical world, which will be big produce next to you.If you are in New York, it will produce in New York. If you are in Beijing, will be produced in Virgin and shipped to you the same day. So the impact on the environment in terms of sustainability is huge and their efficiencies and believable, and the creativity is unleashing the creativity for the designers and for the brands.W why is no one else doing this? Or are they well, uh, there are some, uh, companies, our customers that using our technologies like Amazon are doing it. If you go to Amazon and you're doing what you're doing, right. That's what I meant because, well, we are kind of unique festival in terms of the physical world.We out technology, what we have developed is systems Inc services that is all sustainable, which are digital systems that can produce one off. If you want it to produce a t-shirt or any, any government or any fabric in the, in, in the past using analog technology, you had to print where to produce hundreds of meters in order that it will be economical and.The sustainability impact is huge. Um, there's a lot of pollution and consumption of water for every meter without technology, because it's digital, you are not limited. You can print one t-shirt, you can print one meter, one fit, there's no limitation and every feed can be different design. So this is the advantage of digital is unleashing the limitations that you had before, and we are not using water.So there's no, there's no water consumption. It's pigment ink. So it's fully green. So no impact on the environment. So like who couldn't use corny Amazon obviously, but they're the largest retailer in the world could, could, could I use it on my online Shopify store that make, that sells? I dunno, 10 shirts a year.Exactly the point it's off form. The biggest retailers, biggest e-commerce biggest brands like Adidas, Nike. They of course can use it to anyone, any consumer that would like to open a shop in Shopify. Now, what is the problem with Shopify? If you are now at this time? And you see somewhere in India and you would like to, to sell your product.You open the shop in Shopify in five minutes, you put your design, what is the problem? Once you get the order, what are you going to do with it? How are you going to produce it? Are you going to ship it out? We can compete against other marketplaces. What call Nita Naples is to connect all those and marketplaces all those designers in to a network of fulfiller that can fulfill for them.So you need to take care of only on the design, open a shop, and then connected to Coney ticks. And kinetics is a platform that connect them to a network or fulfiller that using our technology and can produce it anywhere around the world. And it sounds good. The market clearly likes it. Cause if you, if you look at your stock, it's had a pretty tremendous run actually, even, even last year, uh, seemed to, uh, COVID, didn't seem to hold it down too long.So, uh, the market agrees with you. Uh, so I, I guess keep doing what you're doing. Uh, running Samuel was the CEO of, uh, coordinate, uh, digital. Uh, we will have to get you back on the show. Uh, hopefully, uh, now maybe next year when, when the supply chain starts to work itself out a little bit, but I, I I'm, I'm very curious about this space because, uh, you're, you're one of the best performing stocks, uh, I think out there probably right now.So, uh, Ronan, thank you so much for coming on the show today. Thank you very much. Pleasure being here. All right. Uh, it is, uh, 1259. We've got our next guest coming on in couple minutes. Whenever minute when it, whenever they join, to be honest, cause they're not even here yet, but that's okay. Uh, Scott Mathis is the CEO and chairman of Gacha holdings, ticker V I N L a.And then we have, I'm very excited for our one to 30 guests, but we're not a Capels from Benzinga and, uh, really Benzinga is, is a side it's his side gig. His main gig is, uh, is doing really complex. Trading stuff, strategies. So, uh, I'm, I'm very, I'm very much looking forward to that, uh, in a half hour. Uh, if we can think of who executive though, and I have not grabbed, voted for likes yet this hour as we enter our two of our show keyword yet, uh, if you could be so kind and hit that thumbs up button on your screen, I'm not sure where we're at on the light counter right now.Let's look, we're at the de come on computer 74, 75. We can do better than that. We do over a hundred easy, easy. The goal for the goal for the day is 200, but we can get you a hundred right now. I suspect. Yeah. So before we get to Scott Mathis with a wild show holdings, um, the, uh, the previous guest, I liked that idea of cause basically what he's saying is that companies now are producing clothes for a year down the line, right?But they don't know what's going to be hot on Instagram and Tik TOK and what the trends are going to be efficient. It's not efficient. So what, what he's saying they're doing is waiting and basically it's print on demand, but on a huge scale, like what Shelly was talking about in the chat with the economies of scale, they're able to produce, uh, the goods for cheaper when they're doing it on a large scale.If everyone, if they're, if their technology is able to kind of shift that whole industry, it would have a tremendous impact on, uh, the environmental right now, the negative environmental impact that the textile industry has. Another fun fact. Spencer, did you know this, that a lot of luxury brands, um, such as, you know, Gucci, Louis Vuitton, do you know what they do with their extra extra goods?No, I don't want to say something that's politically incorrect, but I know I have no idea. What could, what would the, I don't know. They, they, they, they give it the, give it to animals. I don&

In this episode, Ledge chats with Brandon Smith, Director of Engineering at eVestment, about scaling high-growth engineering teams and delivering cloud-native financial technology solutions. See acast.com/privacy for privacy and opt-out information.

On Episode #41 of the Gruler Nation Podcast we are joined by Andrew Swan, CEO, of IDX Advisors and IDX Insights and Ben McMillan, CIO, of IDX Advisors and IDX Insights. Investment research and technology are at the core of IDX's business, and the intersection of these two worlds provides powerful solutions for the investment company, which places them at the forefront of that paradigm shift. Andrew Swan is former co- founder and President of Bastion Quantitative Sciences, a Quantamental Macro Hedge Fund firm based in New York. From 2016 through 2018 he oversaw the formation, operational development, and strategic guidance of the business. Prior to that, he served as Managing Director of Longboard Asset Management, a liquid alternatives CTA based in Phoenix. Andrew graduated from Arizona State University with a BS in Finance. Ben McMillan was most recently a portfolio manager at RQSI where he launched the RQSI Small Cap Hedged Equity Mutual fund. He also served as co-­Portfolio manager (and co-creator) of the Van Eck Long/Short Equity Index mutual fund. Ben also founded the cloud-­based 13F analytics platform, AlphaStratus, which was acquired by eVestment in 2012. Ben holds an MSc in Econometrics from the London School of Economics as well as an MA and BA in Economics from Boston University. Check out their websites to learn more! IDX Insights (Research & Index Creator): https://idxinsights.comIDX Advisor (Asset Manager & OCIO): https://indadvisors.comOr shoot them an email at info@idxadvisors.com#IDXAdvisors #CEO #CIO #advisers #insights #investmentresearch #technology #investment #operationaldevelopment #econ #finance #podcast #GrulerNation #GrulerNationPodcast #gnp #arizonapodcast #scottsdale #yesphx #phx The Gruler Nation Podcast is a show that focuses on conversations with interesting "Level 10" people passionate about changing the world with their work, relationships and ideas. The show is hosted by Robert Gruler, an attorney and founding partner of the R&R Law Group, a criminal defense law firm based in Scottsdale, Arizona focused on helping good people charged with crimes move forward with their lives. Interested in being on the show? Email Robert directly at robert@rrlawaz.com or visit www.robgruler.com for more information. Support the show (https://www.ericshouse.org/donate/)

For the last 18 years, Tate Haymond has been in the sales space. Whether it be directly selling or managing salespeople, or managing sales managers to help them hone their craft. While at eVestment, Tate has been a part of 7-8 mergers and acquisitions, which has given him first-hand experience working in the midst of multiple sales culture evolutions. For Tate, a process driven approach to sales and culture is key.

Data geek, mathematical wiz, the guy who skates to where the puck is going and unique. This is Michael Magnan in a nutshell. Michael is a forward thinker that is a leader in a space that is in high demand but has very little people smart enough to tackle. Data is king, but being able to create actionable insights on the data is what makes data powerful. Michael has that special power of taking data and creating predictive analytics out of it, which powers decisions and creates more personable experiences. He's been with the big guys, taking his powers to eVestment, which was recently acquired by Nasdaq. Afterward, he left to start his own company, PlanPro, to disrupt the 401k advisor space. Our future decisions will be powered by algorithms created by people like Michael and we are lucky enough to explore the future with one of the brightest minds that will drive where we go with the abundant data we have

Talking with Drake Paulson and Graeme Faulds from eVestment, a Nasdaq company, about the results of their 2018 Private Markets Due Diligence Survey. Find out how Limited Partners feel about fees, the use of credit facilities to close deals and due diligence.

In this episode of SoundNotes, Liana Dore, the Agile Governance Lead for eVestment explains why eVestment chose to establish a group focused on Agile Governance instead of a traditional PMO. Liana explains how Agile Governance works at eVestment, what she does day to day and the positive impact it has had on the Agile teams. Show Notes: Intro and background on eVestment 1:48 What is an Agile Governance Lead 3:30 Making the choice to establish Agile Governance instead of a traditional PMO 3:56 What does an Agile Governance Lead do all day 5:02 How Agile Governance works differently than a traditional PMO 7:40 The benefits of training the team all at once 13:30 Understanding Team Health in an Agile organization 16:05 Creating a space for the teams to thrive 18:44 Establishing an entrepreneurial culture that can scale 20:43 Agile Governance is not about control. It has to be light touch 23:32 How to get in touch with Liana 24:35 If you’d like to get in touch with Liana, you can reach her via LinkedIn at https://www.linkedin.com/in/lianadore

Learning Insights Radio provides case studies, lessons learned, and leading-edge business practices from learning leaders and TrainingPros Relationship Managers across the country.       Michele Shauf / evestment Director of Learning and Development     The post Michele Shauf with eVestment appeared first on Business RadioX ®.